The effect of colon cancer on muscle gene expression, body composition, muscle function, and muscle metabolism

The effect of colon cancer on muscle gene expression, body composition, muscle function, and muscle metabolism - COMUNEX

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55854

Enrollment

Registered

2016-10-10

Start date

2017-04-25

Completion date

Unknown

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(colon cancer) cachexia body mass losse in cancer patients muscle loss in cancer patients

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria CC patients: In order to be eligible to participate in this study, a subject must meet all of the following inclusion criteria: • Diagnosed with primary colon cancer (30) or liver metastases (10) • Eligible for a tumor resection procedure Controls: • Eligible for elective laparoscopic surgery (*, 10; *, 5), for a cause that is not associated with infections orinflammation, for example cholestectomy patients, patients undergoing an inguinal hernia repair or an abdominalhysterectomy

Exclusion criteria

Exclusion criteria: Exclusion criteria CC patients: A potential subject who meets any of the following criteria will be excluded from participation in this study: • Having had chemotherapy or an operational procedure of the abdomen in the past 6 months • Suffering from malabsorption Controls: • Having had treatment for previous or current tumors

Design outcomes

Primary

Measure	Time frame
• Muscle gene expression: transcriptomic analyses of muscle biopsy	—

Secondary

Measure	Time frame
• Body composition: measured in abdominal CT-scan used for diagnosis. • Physical and functional wellbeing and anorexia/cachexia: subscales of the Functional Assessment of Anorexia/Cachexia Therapy questionnaire will be determined (together leading to the FAACT Trial Outcome Index (TOI)). • Metabolic markers: kinase analysis from muscle biopsy and analysis of the presence of lipolysis in the visceral and subcutaneous fat biopsies. • Biochemical markers: blood cytokine levels, inflammation markers, hemoglobin content and serum albumin levels. • Nutritional markers: blood micronutrient levels (e.g. blood glucose, cholesterol, triglycerides, vitamins etc.). • Muscle function parameters: o Histological analysis: to determine fiber type distribution, muscle fiber size, number of myonuclei, number of satellite cells, muscle fiber oxidative capacity o Single fiber contractile properties: force-velocity characteristics of single muscle fibers taken from the biopsy o Muscle strength: grip strength • Fat gene expression: transcriptomic analyses of fat biopsy	—

Measure

Time frame

• Body composition: measured in abdominal CT-scan used for diagnosis. • Physical and functional wellbeing and anorexia/cachexia: subscales of the Functional Assessment of Anorexia/Cachexia Therapy questionnaire will be determined (together leading to the FAACT Trial Outcome Index (TOI)). • Metabolic markers: kinase analysis from muscle biopsy and analysis of the presence of lipolysis in the visceral and subcutaneous fat biopsies. • Biochemical markers: blood cytokine levels, inflammation markers, hemoglobin content and serum albumin levels. • Nutritional markers: blood micronutrient levels (e.g. blood glucose, cholesterol, triglycerides, vitamins etc.). • Muscle function parameters: o Histological analysis: to determine fiber type distribution, muscle fiber size, number of myonuclei, number of satellite cells, muscle fiber oxidative capacity o Single fiber contractile properties: force-velocity characteristics of single muscle fibers taken from the biopsy o Muscle strength: grip strength • Fat gene expression: transcriptomic analyses of fat biopsy

—

Countries

Netherlands

Outcome results